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Abstract
Purpose: In spite of intense research efforts, pancreatic ductal adenocarcinoma remains one of the most deadly
malignancies in the world. We and others have previously identified a subpopulation of pancreatic cancer stem cells within
the tumor as a critical therapeutic target and additionally shown that the tumor stroma represents not only a restrictive
barrier for successful drug delivery, but also serves as a paracrine niche for cancer stem cells. Therefore, we embarked on a
large-scale investigation on the effects of combining chemotherapy, hedgehog pathway inhibition, and mTOR inhibition in
a preclinical mouse model of pancreatic cancer.
Experimental Design: Prospective and randomized testing in a set of almost 200 subcutaneous and orthotopic implanted
whole-tissue primary human tumor xenografts.
Results: The combined targeting of highly chemoresistant cancer stem cells as well as their more differentiated progenies,
together with abrogation of the tumor microenvironment by targeting the stroma and enhancing tissue penetration of the
chemotherapeutic agent translated into significantly prolonged survival in preclinical models of human pancreatic cancer.
Most pronounced therapeutic effects were observed in gemcitabine-resistant patient-derived tumors. Intriguingly, the
proposed triple therapy approach could be further enhanced by using a PEGylated formulation of gemcitabine, which
significantly increased its bioavailability and tissue penetration, resulting in a further improved overall outcome.
Conclusions: This multimodal therapeutic strategy should be further explored in the clinical setting as its success may
eventually improve the poor prognosis of patients with pancreatic ductal adenocarcinoma.
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Introduction
Pancreatic ductal adenocarcinoma (hereafter referred to as
‘‘pancreatic cancer’’ or PDAC) is the fourth most frequent cause of
cancer-related death world-wide [1,2,3] and is characterized by a
high rate of metastasis and pronounced resistance to chemother-
apy and radiation. Despite extensive research efforts over the past
decades, little substantial progress has been made towards
improving clinical endpoints [4]. Although the introduction of
the anti-metabolite gemcitabine in 2007 has improved clinical
response by reducing pain and weight loss [5], disease prognosis
has remained extremely poor with a 5 year survival rate of,3–4%
and a median survival period of 4–6 months [1,6]. Indeed, several
studies have consistently shown that gemcitabine treatment mostly
targets differentiated cancer cells resulting in a relative enrichment
of cancer stem cells [7,8,9]. For patients with metastatic disease,
but good performance status, the recent combination therapy
FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucov-
orin) showed a significant survival advantage but with increased
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toxic side-effects [10]. Alternatively, the regimen of nab-paclitaxel
plus gemcitabine showed substantial anti-tumor activity with more
tolerable adverse effects in a phase I/II trial, warranting phase III
evaluation [11]. However, in all these trials the majority of the
patients ultimately succumbed from disease progression. Thus, the
development of new anti-cancer therapeutics and/or new treat-
ment modalities remains a high healthcare priority.
With increasing evidence supporting the existence of cancer
stem cells, a new horizon is emerging in the development of
therapeutic strategies against pancreatic cancer. Cancer stem cells
represent a subpopulation of cells distinguishable from the bulk of
the tumor based on their exclusive ability to drive tumorigenesis
and metastasis. These cells also play a crucial and driving role in
disease relapse [12,13,14,15,16]; therefore, the elucidation of the
mechanisms underlying pancreatic tumorigenesis and especially
pancreatic cancer stem cells is of crucial relevance for the
development of more efficient clinically-available therapies.
Indeed, we have recently developed novel approaches that both
target cancer stem cells and overcome their mechanisms of chemo-
resistance [9,17,18]. For example, we have shown that the self-
renewal capacity of pancreatic cancer stem cells is dependent on
both Hedgehog and mTOR signaling, and simultaneous targeting of
these two pathways, in combination with Gemcitabine, represents
a novel treatment strategy for epithelial cancers such as pancreatic
cancer [9]. Building on these studies, we here investigate the
applicability, safety, and potential for further optimization of this
combination therapy approach in a large set of primary patient-
derived tumors.
Results
Triple Therapy Markedly Reduces Tumor Size and
Increases Survival
We have shown previously that sphere cultures of pancreatic
cancer cells enrich for cancer stem cells [8,9,17], and that
combined targeting of the Sonic Hedgehog (SHH) and mTOR
pathways may offer a new therapeutic option. Here we verify in
four distinct primary pancreatic cancer cell lines derived from
patient tumors that cancer stem cell-enriched sphere cultures
indeed show marked overexpression of SHH and the Hedgehog
target genes GLI-1 and GLI-2 (Fig. 1A), as well as increased
mTOR pathway activity (Fig. 1B). The subsequent in vivo
evaluation of the combination therapy was performed in clinically
most relevant models of patient-derived pancreatic cancer whole-
tissue xenografts (see Fig. 1C for study design). Pieces of briefly
in vivo expanded primary human pancreatic tumors containing
heterogeneous populations of cancer cells including cancer stem
cells [9] as well as stromal cells [7], pancreatic stellate cells,
inflammatory cells, and extracellular matrix were implanted
subcutaneously and orthotopically into immunocompromised
mice. Tumor take rate was confirmed by tumor growth during
two successive size measurements, and tumor-bearing mice were
randomized for treatment. Subsequently, the tumors were
measured once weekly either by caliper (subcutaneous tumors)
or with a small-animal ultrasound imaging system (orthotopic
tumors). As Gemcitabine (Gem) represents the current standard
treatment for pancreatic cancer, we used Gem-treated mice as the
reference group.
A set of representative tumors was selected based on their
diverse response to Gem treatment [7]. PDAC-265 and 185 were
highly resistant to Gem treatment, showing rapid tumor growth so
that the first mice had to be removed from the study within 3
weeks of the start of the treatment (Fig. 2A–E) due to excessive
tumor growth. In contrast, in tumors PDAC-JH051, 247, and
Pax22, Gem treatment resulted in initial treatment response and
disease stabilization; however, after the removal of chemotherapy,
the tumors reproducibly started to re-grow (Fig. 2C–E). Of all the
tumors investigated, only PDAC-354, which does not carry Kras
mutations [19], showed significant response to Gem treatment
until the end of the observation period (Fig. 2F) and closely
mimicked the treatment response observed in the actual patient
(data not shown).
Importantly, we were able to improve treatment response by
combining chemotherapy with the novel hedgehog pathway
inhibitor SIBI-C1 (SIBI; Siena Biotech) [20]. SIBI strongly inhibits
gene expression of SHH and downstream target genes such as
GLI2 in primary pancreatic cancer cells in vitro (Fig. S1A in File
S1). SIBI was administered for only 3 weeks to reduce potentially
deleterious effects. Gem was given for a total time period of 60
days in accordance with common clinical practice (Fig. 1C). Due
to the strong response to chemotherapy alone, co-treatment of
mice bearing PDAC-354 xenografts with either SIBI did not show
an additional effect at the level of tumor size (Fig. 2F) or survival
(data not shown). For all of the other tumors, however, double
treatment with Gem+SIBI led to a marked reduction in tumor size
(dashed line, Fig. 1 & 2), significant delay in tumor growth, and
thus significantly prolonged survival compared to mice receiving
either no treatment or Gem+Vehicle (Fig. 2G). Importantly,
however, tumors eventually relapsed limiting survival in mice
receiving this double therapy. These data are in line with
improved delivery of gemcitabine following depletion of protective
stromal tissue [21]. As previously shown, inhibition of hedgehog
signaling alone does not completely abrogate the cancer stem cell
population (Fig. 3A & B) [9].
Since we have shown in comprehensive in vitro studies that
cancer stem cells can indeed be eliminated by the addition of an
inhibitor of the mTOR pathways [9], we next investigated the
effect of a treatment regimen comprising Gem, SIBI, and
established mTOR inhibitor rapamycin (Rapa) on our represen-
tative panel of primary pancreatic cancer tissue xenografts.
Interestingly, we observed a very strong response to this triple
therapy, resulting in disease stabilization or even regression in
almost all tumors investigated (dotted line, Fig. 1 & 2). This
translated into a significantly improved cumulative survival as
compared to all other treatment groups (Fig. 2E).
Combination Therapy Depletes Cancer Stem Cell Content
and Alters Tumor Composition
In order to evaluate the in vivo effects of combination therapy on
cancer stem cell populations, we explanted and digested repre-
sentative tumors of each group after completion of the 3 weeks of
triple therapy, and analyzed by flow cytometry the expression of
surface markers previously linked to a cancer stem cell phenotype
[8,9,13]. The percentage of EpCAM+CD133+CD44+ cells in
Gem-treated tumors was regularly 2-3-fold higher as compared to
untreated tumors [data not shown and [8]]. In contrast,
Gem+SIBI already showed a slight decrease in cancer stem cell
numbers as compared to Gem alone (Fig. 3A & B). Importantly,
only the addition of Rapa to the treatment regimen virtually
eliminated cancer stem cells from the tumor. Furthermore, upon
termination of the study period (day 200) we investigated
secondary sphere formation as a functional assay for cancer stem
cell activity in PDAC-Pax22 tumors and observed that sphere
formation capacity was slightly diminished for cultures derived
from tumors treated with Gem+SIBI as compared to Gem alone.
Interestingly, however, it was only after triple treatment that we
could observe complete abrogation of sphere formation activity
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(Fig. 3C), suggesting that triple combination therapy had
effectively depleted the cancer stem cell pool in the tumor.
More detailed histological investigation of the tumors showed
that the different treatment regimens also modified the cellular
composition of the tumor. While the primary tumor-derived
Figure 1. Targeting of sonic hedgehog and mTOR in pancreatic ductal adenocarcinoma. (A) Fold increase mRNA expression levels of SHH,
GLI-1, and GLI-2 of sphere-derived vs. adherent cells. (B) Western blot analysis of mTOR pathway activity via the assessment of S6 kinase expression
(upper panel) and phosphorylation (lower panel) in adherent primary cells versus stem cell-enriched sphere-derived cells. (C) Illustration of
experimental setup. Duration of triple therapy is marked by a dark grey box (day 21 to 48), Gem monotherapy with a light grey box (day 48 to 81).
doi:10.1371/journal.pone.0066371.g001
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xenografts used for this study displayed a reasonably high amount
of stroma (35–70%) in the groups treated with Gem only (Fig. 4A,
left panels), the addition of a hedgehog pathway inhibitor
markedly decreased the stroma content (Fig. 4A, middle
panels), an observation that is well in line with previous
published reports [21]. This effect was slightly more pronounced
after the addition of Rapa (Fig. 4A, right panels), and was
statistically significant as compared to tumors treated with Gem
alone (Fig. 4B). As expected, we observed the same effects after
treatment of Gem-sensitive tumors (Fig. S1B in File S1).
Interestingly, we observed similar effects in orthotopic tumors
(Fig. 4A) as in subcutaneous tumors (Fig. S1B in File S1).
Figure 2. Combination therapy in a representative set of pancreatic ductal adenocarcinoma. (A–F) Tumor growth curves for primary
whole-tissue xenografts PDAC-265, PDAC-185, JH051, 247, Pax22, and 354 implanted subcutaneously and orthotopically. Continuous line depicts
Gem+vehicle, dashed line depicts Gem+SIBI, dotted line depicts Gem+SIBI+Rapa (n$6 per group). (G) Kaplan-Meier Curve depicting cumulative
survival time of all mice pooled by treatment group.
doi:10.1371/journal.pone.0066371.g002
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Figure 3. Effect of combination therapy on cancer stem cell content. (A) Representative flow cytometry plots and (B) quantification of cancer
stem cell (EpCAM+CD133+CD44+) content of tumors in the respective treatment group (cumulative results of cells obtained from different
xenografts). (C) Representative images and quantification of secondary sphere formation of treated PDAC-Pax22 tumors explanted at the end of the
experiment (d200).
doi:10.1371/journal.pone.0066371.g003
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PEGylation of Gemcitabine further Enhances the Effects
of Combination Therapy
Since previous reports have shown that modifying the chemical
structure of Gem by PEGylation leads to significantly increased
circulation time and tissue penetration in vivo and may therefore be
a novel option for the improved treatment of patients with
(pancreatic) cancer [22,23], we decided as a next step to determine
the effects of PolyEthyleneGlycol-bound Gem (PEG-Gem) as the
extended in vivo circulation time and higher tissue penetration of
PEG-Gem may generate superior effects as compared to standard
Gem. First, we evaluated the in vitro effects of PEG-Gem as
compared to Gem on freshly isolated primary human pancreatic
cancer cells. For this purpose, four matching primary cell cultures
generated from in vivo-expanded pancreatic cancer tissues were
treated for 48 hours with either standard Gem or PEG-Gem and
were subsequently analyzed by flow cytometry for the induction of
apoptosis or cell death, as well as for their cancer stem cell content.
Regarding the percentage of apoptotic and dead cells, no
differences could be observed between treatment groups (Fig. 5A
left panel, and data not shown). In addition, we did not
observe differences between standard Gem and PEG-Gem
treatment regarding the content of CD133+ cells in vitro (Fig. 5A
right panel).
Next we treated mice bearing orthotopic or subcutaneous
primary tumor-derived whole-tissue xenografts with PEG-Gem,
analogous to the treatment regimen for standard Gem. We
selected tumors that showed insufficient response with Gem. While
we did not observe a significant difference for median survival
between PEG-Gem and standard Gem for these tumors (Fig. 5B),
it is important to note that the onset of tumor-related death in
mice treated with PEG-Gem was far later than with standard Gem
(Time until progression: PEG-Gem 91d vs. Gem 19d). Encour-
Figure 4. Effect of combination therapy on tumor composition. (A) Representative histological pictures showing stroma content in the
respective treatment groups in gemcitabine resistant orthotopic tumors (PDAC-185, upper panel), (Pax22, lower panel). (B) Quantification of
stroma content throughout the different treated xenografts.
doi:10.1371/journal.pone.0066371.g004
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aged by these promising results, we next replaced standard Gem
treatment with PEG-Gem in the triple therapy approach (PEG-
Gem+SIBI+Rapa) and evaluated the effects on tumor growth and
survival in mice bearing PDAC-185 patient-derived xenografts.
While in our initial in vivo studies Gem+SIBI+Rapa treatment led
to significantly reduced tumor growth and short-term sustained
disease as compared to standard Gem treatment (Fig. 2D), many
tumors eventually relapsed. In response to treatment with PEG-
Gem+SIBI+Rapa, however, we observed virtually complete
regression of the tumors (Fig. 5C), which resulted in 100%
survival until the end of the observation period (day 125) (Fig. 5D).
Combination Therapy Shows no Significant Toxicity
Potential toxicity remains a major concern for combination
therapy approaches. To assess cumulative toxicity of the admin-
istered treatments and their respective combinations, we recorded
body weight for all treated mice on a weekly basis, starting on the
day of randomization until day 100. Excluding cachexia as a
potential treatment-induced side effect, no significant differences
in body weights were observed between the treatment groups
(Fig. 6A), Furthermore, in order to exclude potentially deleterious
effects on the function of normal stem cells (e.g. in the
hematopoietic system), we additionally monitored white blood
cell numbers in the treated mice at the completion of the 3 weeks
of single versus combined therapies. While at this point of the
study the expected cumulative toxicity would be the highest, no
significant reduction in white blood cell counts was observed in
any of the treatment groups as compared to standard Gem
treatment (p = 0.792) (Fig. 6B), suggesting no extensive alterations
of hematopoietic stem cells by the triple combination treatment.
Interestingly, even the increased circulation time and improved
tissue penetration of PEG-Gem did not significantly increase
expected adverse side effects as compared to standard Gem
treatment (Fig. 6A & B).
Discussion
Here we validate the concept of a multimodal therapy for
comprehensively targeting the diverse cell compartments in
pancreatic cancer using a representative set of almost 200
subcutaneous and orthotopic whole-tissue primary tumor xeno-
grafts, making this one of the largest investigations in the cancer
stem cell field. Tumors were selected based on their previously
described diverse response to gemcitabine treatment [7]. Chemo-
therapy and radiation primarily target differentiated cancer cells,
and while these therapies induce apoptosis and cell death in tumor
cells, a population of cancer stem cells is highly resistant
[8,9,18,24], survives the standard therapy, and maintains the
ability to re-populate a tumor in all its heterogeneity. Double
treatment combining Gem and the new Smoothened inhibitor
SIBI consistently prolonged survival in mice transplanted with
tumors. Importantly, however, only in mice treated with triple
therapy cancer stem cells were virtually completely abrogated, and
we observed a long-term disease stabilization or regression, and
subsequent long-term survival. In this combination regimen, the
treatment effect of conventional Gem could be further enhanced
by the use of PEGylated Gem via enhancing its bioavailability.
At the histological level, pancreatic cancer is characterized by
very dense stroma and poor vascularization. Olive et al. showed in
a genetically engineered mouse model of pancreatic cancer that
the stroma is strongly dependent on hedgehog signaling, and
inhibition of the hedgehog pathway with smoothened inhibitors
leads to ‘‘preferential’’ killing of stromal cells and increased vessel
density [21], thus making tumor cells more accessible to
therapeutic intervention. While these observations were obtained
in a mouse model of pancreatic cancer, we have more recently
shown that also in patient-derived whole-tissue xenografts co-
treatment with a smoothened inhibitor significantly increases drug
delivery [17] and markedly reduces tumor-associated stroma
formation. Importantly, we now appreciate that the stroma not
only hampers drug delivery [21], but also provides a supportive
niche for cancer stem cells promoting their self-renewal capacity
and invasiveness [25]. Thus, elimination or abrogation of the
stroma does significantly improve treatment regimens by distinct
mechanism, but is only capable of eliminating cancer stem cells if
combined with Gem.
However, despite the rather modest response of cancer stem
cells to hedgehog pathway inhibition as a single agent, we were
able to demonstrate that smoothened inhibitors are still essential in
order to successfully eliminate chemoresistant pancreatic cancer
stem cells if combined with other stem cell-targeting agents [9,17].
Specifically, we have previously shown for pancreatic cancer that a
combination of chemotherapy and inhibitors of both mTOR and
hedgehog signaling eliminates differentiated cells as well as cancer
stem cells in vitro [9], and that this translates into long-term
survival in vivo. Recently, Wang et al. provided an important
mechanistic link for the combined inhibition of the hedgehog and
mTOR pathway. Specifically, the authors demonstrate that
mTOR/S6K1 signaling results in phosphorylation of Gli and
subsequent expression of downstream targets. Inhibition of both
pathways greatly enhanced the pro-apoptosis effect of inhibition of
either inhibition alone [26]. In the present study, we now saw a
virtually complete elimination of cancer stem cells for this
combination therapy in a large and representative set of primary
xenografts. Whereas flow cytometry using the surface markers
CD133, EpCAM, and CD44 already suggested that the cancer
stem cell content was strongly reduced, functional assays (e.g.
sphere formation assay) validated that the cells isolated from the
explanted tumors indeed were unable to form tumor spheres
in vitro, strongly suggesting that the cancer stem cell population as
the root of the disease, had been effectively targeted by the triple
combination.
Even though the results using Gem-SIBI-Rapa were highly
consistent and encouraging across a panel of patient-derived
tumors, we did observe tumor re-growth in some mice (e.g.
PDAC-185 xenografts) and, subsequently, a decrease in the
survival of these xenograft-bearing animals. As this might be
related to the limited bioavailability of the chemotherapeutic agent
as an essential part of this combination therapy, we further
advanced our treatment strategy by modifying the chemotherapy.
Specifically, Vandana et al. have recently shown that modifying
gemcitabine via PEGylation leads to enhanced bioavailability in
the circulation as compared to native gemcitabine. Although they
Figure 5. Comparison of the in vitro and in vivo effects of Pegylated Gemcitabine. (A) In vitro effects of Gem and PEG-Gem on apoptosis
and cell death as well as CD133 expression (cumulative results of cells obtained from different xenografts). (B) Kaplan-Meier Curve depicting
cumulative survival time of all mice pooled by treatment group. For illustrative purposes, selected survival curves of Fig. 2D are depicted again. (C)
Tumor growth curves for primary whole-tissue xenografts implanted subcutaneously and orthotopically, respectively. Continuous line depicts
Gem+vehicle, dashed line depicts Gem+ SIBI, dotted line depicts Gem+SIBI+Rapa. (D) Kaplan-Meier Curve depicting cumulative survival time of all
mice pooled by treatment group. For illustrative purposes, selected survival curves of Fig. 2D are depicted again.
doi:10.1371/journal.pone.0066371.g005
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have also shown better in vitro response of established pancreatic
cancer cells using PEGylated gemcitabine as compared to the
regular formulation [22], we observed no significant differences
between Gem and PEG-Gem in vitro at the level of cancer stem cell
content or induction of apoptosis or cell death using xenograft-
derived primary cells. While these data are not surprising as drug
delivery and availability is not a critical issue in vitro, the results
clearly emphasize the importance of utilizing primary cancer tissue
for further in vivo evaluation of drug efficacy.
Indeed, we were then able to validate and extend this concept to
the in vivo setting by showing that PEG-Gem treatment signifi-
cantly delayed the time of tumor progression by 72 days. This
enhanced treatment response is certainly impressive as it
represents more than half of the study period. As expected,
however, tumors ultimately progressed resulting in virtually no
difference in median survival of the PEG-Gem treated mice
compared to mice treated with traditional Gem alone. While these
data confirm that PEGylation of Gem does indeed improve drug
availability and delivery, respectively, by enhancing the circulation
time and tissue penetration, as expected, PEG-Gem alone is
clearly not sufficient to overcome the chemoresistance of cancer
stem cells. Therefore, we next investigated the effects of replacing
regular Gem with PEG-Gem in our multimodal approach for
targeting pancreatic tumors, which had originally responded to
Gem+SIBI+Rapa treatment, but eventually relapsed under this
specific treatment regimen. Intriguingly, using the PEG-Gem+SI-
BI+Rapa combination we not only observed virtually complete
tumor regression, but most importantly we obtained 100%
survival throughout the 125d study period in this highly therapy-
resistant tumor. While this observation does not exclude later re-
growth as seen in PDAC-Pax22, these data are very promising and
are consistent with the notion that further improving the
formulation of the combined drugs is mandatory for extending
in vitro findings to the much more complex in vivo setting.
The utilized new smoothened inhibitor SIBI-C1 (Siena Biotech,
Italy) was also highly effective in vivo, as can be seen by reduced
tumor growth in combination with Gem and thus significantly
enhanced survival time. Furthermore, SIBI can be safely
administered in vivo, as we saw no adverse effects on total body
weight or white blood cell counts. Importantly, this is well in line
with previous observations using other smoothened inhibitors
[9,15]. The Gem+SIBI+Rapa combination therapy also showed
no significant toxicity compared to Gem treatment alone during
the course of the experiments. PEG-Gem+SIBI+Rapa combina-
tion treatment, while much more effective in vivo, only slightly, but
non-significantly decreased white blood cell counts and had no
effect on the body weight of the animals as compared to respective
controls. It is important to note, however, that the healthy and
relatively young mice used for this study are likely more capable of
compensating for putative adverse effects on the normal stem cell
Figure 6. Assessment of in vivo biocompatibility/safety. (A) Body weights were recorded for all mice throughout the first 100 days of the
experiment. (B) White blood cell counts of all mice were assessed at the end of the administration period of the triple combination.
doi:10.1371/journal.pone.0066371.g006
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compartments during triple therapy treatment. Therefore, it will
be important to further validate the safety of this treatment
regimen in human patients in order to ultimately apply it to the
mostly aged and moribund patients suffering from pancreatic
cancer.
In conclusion, here we provide compelling evidence for the
efficacy of a multimodal therapy targeting differentiated cells as
well as cancer stem cells in pancreatic cancer, resulting in long-
term survival in mice. Thus, these data confirm and expand
previous findings from our laboratory in a very large cohort of
animals with patient-derived pancreatic cancer xenografts
[9,15,17]. In addition, we also offer a new and novel perspective
on how to further improve current therapeutic approaches by
modifying the molecular structure of the mandatory chemother-
apeutic agents using PEGylation. Taken together, these findings
should significantly impact the future development of new anti-
pancreatic cancer therapeutics and/or treatment modalities.
Materials and Methods
Tumor Samples
After patients’ informed consent had been obtained, excess
tissues from resected pancreatic carcinomas was xenografted at
Johns Hopkins Medical Institutions (JHMIRB: 05-04-14-02 ‘‘A
Feasibility Study for Individualized Treatment of Patients with
Advanced Pancreatic Cancer’’) and Hospital de Madrid - Centro
Integral Oncolo´gico Clara Campal (FHM.06.10 "Establishment of
bank for tumors and healthy tissue in patients with cancer’’),
respectively, under the indicated Institutional Review Board-
approved protocols [7]. Briefly, excess tumor tissues not needed for
clinical diagnosis during routine Whipple resections performed by
surgeons that were not involved in the present study were
subsequently implanted into immunocompromised mice. All
patient information was made anonymous by removal of any
information, which identifies, or could lead to the identification of
the patient. None of the patients had undergone neoadjuvant
radiation or chemotherapy prior to resection of the tumor.
Animal Experiments
All animal experiments were conducted in accordance with
institutional guidelines and were approved by the Institutional
Animal Care and Use Committee of the CNIO (Protocol PA34/
2012– ‘‘Xenotransplant model for human pancreatic cancer’’).
Animals were housed and maintained in laminar flow cabinets
under specific pathogen-free conditions. Briefly, 8 mm3 pieces of
primary, in vivo expanded pancreatic cancer tissue pieces were
either orthotopically or subcutaneously implanted into the
pancreas of 6–8 weeks old female nude mice (Harlan Europe) as
described previously [7,9,27]. For each treatment group, $10
tumors were implanted. Tumor size and body weights of all
animals were measured weekly. Size of the subcutaneous tumors
was measured by caliper and calculated as length6width6depth.
Orthotopic tumors were measured with a dedicated small-animal
ultrasound system (Vevo770, Visualsonics, Toronto, Canada), and
size was calculated as (length6width2)/2. Survival was defined as
the time point when tumors reached 1 cm3 and mice had to be
removed from the study. White blood cell counts were performed
with an Abacus Junior Vet hematology analyzer (Diatron, Lenexa,
Kansas).
Allocated Treatments
Gemcitabine was purchased from Lilly (Indianapolis, Indianap-
olis), dissolved in sterile water and administered twice a week
(125 mg/kg i.p.) for 60 days. Rapa (5 mg/kg; Wyeth, Philadel-
phia, Pennsylvania) was orally administered via the drinking water
as described previously [28]. SIBI and Rapa were administered for
21 days. SIBI-C1 (SEN826) was kindly provided by Siena Biotech
S.p.A. (Siena, Italy). The characteristics of the compound are
similar to that of SEN794 and SEN450, some chemical properties
were ameliorated in each of the compounds. SEN450 has
previously been used and characterized extensively in in vitro and
in vivo tumor models of glioblastoma [20]. SIBI-C1 was dissolved
in a 1:1 mixture of NaCl and polyethyleneglycol (Sigma Aldrich,
St. Louis, Minnesota), and administered at 300 mg/kg by daily
oral gavage. At this dose, SIBI-C1 was found to strongly inhibit the
expression of the Hedgehog target genes GLI-1 and PTCH,
comparable to the inhibitory effects of GDC-0449, in a
subcutaneous medulloblastoma model derived from Patch+/2
mice (unpublished data Siena Biotech). For in vitro experiments,
SIBI-C1 was dissolved in DMSO and used at a concentration of
10 mM.
PEGylated gemcitabine was synthesized by Sahoo and col-
leagues as described previously and with modifications [22], and
was administered analogous to regular gemcitabine. The PEGy-
lated gemcitabine was synthesized by conjugating gemcitabine to
HOOC-PEG-COOH in dimethylsulfoxide (DMSO), in the
presence of triethylamine (TEA). Briefly, HOOC-PEG-COOH
(0.1 mM) was dissolved in 2.5 ml of DMSO to which TEA
(0.05 ml) was added. Further, NHS (100 mM) and EDC
(400 mM) were added to the above solution and the reaction
mixture was stirred for 30 min. Later, the synthesized PEG-
(NHS)2 was coupled to gemcitabine. In brief, the gemcitabine
(0.4 mM) was dissolved in 500 ml and added drop wise to the
PEG-(NHS)2 solution in the presence of 2 mM TEA (PEG-NHS/
Gemcitabine/TEA molar ratio = 1:4:20). The reaction mixture
was then kept on constant magnetic stirring overnight at room
temperature. The reaction mixture was later subjected to dialysis
using a dialysis membrane (MWCO: molecular weight cut-
off = 3.5 kDa) against distilled water to remove free and unreacted
gemcitabine. Subsequently, the dialyzed solution was freeze-dried
using a lyophilizer (Labconco, Kansas City, Montana) at a
temperature of 248uC and 0.05 mbar to obtain the powdered
form of the conjugate. The characterization of the PEGylated
gemcitabine was performed as described previously [22].
RNA Preparation and RT-PCR
Total RNAs from human primary pancreatic cancer cells and
spheres were extracted with TRIzol kit (Life Technologies Inc.)
according to the manufacturer’s instructions. One microgram of
total RNA was used for cDNA synthesis with SuperScript II
reverse transcriptase (Life Technologies Inc.) and random
hexamers. Quantitative real-time PCR was performed using
SYBR Green PCR master mix (Qiagen), according to the
manufacturer’s instructions. The list of utilized primers is depicted
in Table S1 in File S2.
Western Blot Analysis
Total protein extracts were obtained using M-PER Mammalian
Protein Extraction Reagent (Thermo Scientific) supplemented
with phosphatase and protease inhibitors. Pellets were incubated
during 1 h in lysis buffer at 4uC, and centrifuged at 13,000 rpm
during 10 min at 4uC. Total protein concentration was measured
with BCA Protein Assay kit (Pierce) and 25–100 mg protein were
separated by SDS/PAGE and transferred to PVDF membranes.
Upon antibody incubation, membranes were visualized by
enhanced chemoluminescence (Amersham). GAPDH was used
as a loading control. A complete list of used antibodies is included
in Table S2 in File S2.
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Flow Cytometry
To characterize pancreatic cancer stem cells, the following
antibodies were used: anti-CD133/1-APC (clone AC133 Miltenyi
Biotech, Bergisch Gladbach, Germany), anti-CD44-PE anti-
EpCAM FITC (both Becton Dickinson, Heidelberg, Germany)
or appropriate isotype-matched control antibodies. Samples were
analyzed by flow cytometry, using a FACSCanto II (BD), and data
were analyzed with FloJo 9.4.4 (Treestar, Ashland, Oregon).
Apoptosis and cell death analyses were performed using DAPI and
an Annexin V fluorescein isothiocyanate (FITC) staining kit (BD).
Histology
Formalin-fixed, paraffin-embedded tumor sections were stained
with a CK19 antibody (1:500, Dako, Carpinteria, CA), and then
visualized with a rabbit anti-mouse and anti-rabbit HRP-
conjugated antibody (both Epitomics). Nuclear counterstaining
was performed using Hematoxylin. The stroma quantification was
performed by two independent investigators, one an experienced
pathologist (E.G.).
Cell Culture
For in vitro studies, tumors were enzymatically digested with
collagenase and pancreatic cancer adherent cell and sphere
cultures were generated and expanded as previously described
[17,18]. Five thousand cells per milliliter were seeded in ultra-low
attachment plates (Corning B.V., Schiphol-Rijk, Netherlands) and
monitored for sphere formation capacity over the course of 14
days. Spheres were defined as 3-dimensional multicellular
structures of approximately 40 mm or larger. For in vitro
treatment, 105 cells per well were seeded in 6-well plates, treated
with either standard gemcitabine or PEG-Gem at a concentration
of 100 ng/mL after 24 h, and analyzed on day 3 by flow
cytometry to detect apoptosis and cancer stem cell content.
Statistical Analysis
Results for continuous variables are expressed as means 6
standard error of the mean (SEM) unless stated otherwise. Overall
comparison of continuous variables was performed with the
Kruskal-Wallis test followed by post hoc pairwise comparison
using the Mann-Whitney U test. Survival was compared using a
Log Rank test. P values ,0.05 were considered statistically
significant. All analyses were performed with SPSS 19 (SPSS Inc.,
Chicago, IL).
Supporting Information
File S1 Figure S1A: Effect of SIBI-C1 on Hedgehog
pathway gene expression. Fold increase mRNA expression
levels of SHH and GLI2 in gemcitabine resistant primary cancer
cells (PDAC-265 left panel, PDAC-354 right panel). Figure S1B:
Effect of combination therapy on tumor composition.
Representative histological pictures showing stroma content in the
respective treatment groups in gemcitabine resistant subcutane-
ously implanted tumors (PDAC-185, upper panel), (354, lower
panel).
(TIF)
File S2 Table S1: Utilized qRT-PCR primers. Table S2:
Utilized antibodies.
(TIF)
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